Search

Your search keyword '"Georgiopoulos, G."' showing total 650 results
Start Over Author "Georgiopoulos, G."
650 results on '"Georgiopoulos, G."'

2. Mechanisms of Vascular Inflammation and Potential Therapeutic Targets: A Position Paper From the ESH Working Group on Small Arteries

Author

Rios, F, de Ciuceis, C, Georgiopoulos, G, Lazaridis, A, Nosalski, R, Pavlidis, G, Tual-Chalot, S, Agabiti-Rosei, C, Camargo, L, Dąbrowska, E, Quarti-Trevano, F, Hellmann, M, Masi, S, Lopreiato, M, Mavraganis, G, Mengozzi, A, Montezano, A, Stavropoulos, K, Winklewski, P, Wolf, J, Costantino, S, Doumas, M, Gkaliagkousi, E, Grassi, G, Guzik, T, Ikonomidis, I, Narkiewicz, K, Paneni, F, Rizzoni, D, Stamatelopoulos, K, Stellos, K, Taddei, S, Touyz, R, Virdis, A, Rios, Francisco J., de Ciuceis, Carolina, Georgiopoulos, Georgios, Lazaridis, Antonios, Nosalski, Ryszard, Pavlidis, George, Tual-Chalot, Simon, Agabiti-Rosei, Claudia, Camargo, Livia L., Dąbrowska, Edyta, Quarti-Trevano, Fosca, Hellmann, Marcin, Masi, Stefano, Lopreiato, Mariarosaria, Mavraganis, Georgios, Mengozzi, Alessandro, Montezano, Augusto C., Stavropoulos, Konstantinos, Winklewski, Pawel J., Wolf, Jacek, Costantino, Sarah, Doumas, Michael, Gkaliagkousi, Eugenia, Grassi, Guido, Guzik, Tomasz J., Ikonomidis, Ignatios, Narkiewicz, Krzysztof, Paneni, Francesco, Rizzoni, Damiano, Stamatelopoulos, Kimon, Stellos, Konstantinos, Taddei, Stefano, Touyz, Rhian M, Virdis, Agostino, Rios, F, de Ciuceis, C, Georgiopoulos, G, Lazaridis, A, Nosalski, R, Pavlidis, G, Tual-Chalot, S, Agabiti-Rosei, C, Camargo, L, Dąbrowska, E, Quarti-Trevano, F, Hellmann, M, Masi, S, Lopreiato, M, Mavraganis, G, Mengozzi, A, Montezano, A, Stavropoulos, K, Winklewski, P, Wolf, J, Costantino, S, Doumas, M, Gkaliagkousi, E, Grassi, G, Guzik, T, Ikonomidis, I, Narkiewicz, K, Paneni, F, Rizzoni, D, Stamatelopoulos, K, Stellos, K, Taddei, S, Touyz, R, Virdis, A, Rios, Francisco J., de Ciuceis, Carolina, Georgiopoulos, Georgios, Lazaridis, Antonios, Nosalski, Ryszard, Pavlidis, George, Tual-Chalot, Simon, Agabiti-Rosei, Claudia, Camargo, Livia L., Dąbrowska, Edyta, Quarti-Trevano, Fosca, Hellmann, Marcin, Masi, Stefano, Lopreiato, Mariarosaria, Mavraganis, Georgios, Mengozzi, Alessandro, Montezano, Augusto C., Stavropoulos, Konstantinos, Winklewski, Pawel J., Wolf, Jacek, Costantino, Sarah, Doumas, Michael, Gkaliagkousi, Eugenia, Grassi, Guido, Guzik, Tomasz J., Ikonomidis, Ignatios, Narkiewicz, Krzysztof, Paneni, Francesco, Rizzoni, Damiano, Stamatelopoulos, Kimon, Stellos, Konstantinos, Taddei, Stefano, Touyz, Rhian M, and Virdis, Agostino

Abstract

Inflammatory responses in small vessels play an important role in the development of cardiovascular diseases, including hypertension, stroke, and small vessel disease. This involves various complex molecular processes including oxidative stress, inflammasome activation, immune-mediated responses, and protein misfolding, which together contribute to microvascular damage. In addition, epigenetic factors, including DNA methylation, histone modifications, and microRNAs influence vascular inflammation and injury. These phenomena may be acquired during the aging process or due to environmental factors. Activation of proinflammatory signaling pathways and molecular events induce low-grade and chronic inflammation with consequent cardiovascular damage. Identifying mechanism-specific targets might provide opportunities in the development of novel therapeutic approaches. Monoclonal antibodies targeting inflammatory cytokines and epigenetic drugs, show promise in reducing microvascular inflammation and associated cardiovascular diseases. In this article, we provide a comprehensive discussion of the complex mechanisms underlying microvascular inflammation and offer insights into innovative therapeutic strategies that may ameliorate vascular injury in cardiovascular disease.

Published
2024

4. Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19

Author

Marto, J, Strambo, D, Ntaios, G, Nguyen, T, Herzig, R, Czlonkowska, A, Demeestere, J, Mansour, O, Salerno, A, Wegener, S, Baumgartner, P, Cereda, C, Bianco, G, Beyeler, M, Arnold, M, Carrera, E, Machi, P, Altersberger, V, Bonati, L, Gensicke, H, Bolognese, M, Peters, N, Wetzel, S, Magrico, M, Ramos, J, Sargento-Freitas, J, Machado, R, Maia, C, Machado, E, Nunes, A, Ferreira, P, Pinho E Melo, T, Dias, M, Paula, A, Correia, M, Castro, P, Azevedo, E, Albuquerque, L, Alves, J, Ferreira-Pinto, J, Meira, T, Pereira, L, Rodrigues, M, Araujo, A, Rocha, M, Pereira-Fonseca, A, Ribeiro, L, Varela, R, Malheiro, S, Cappellari, M, Zivelonghi, C, Sajeva, G, Zini, A, Gentile, M, Forlivesi, S, Migliaccio, L, Sessa, M, La Gioia, S, Pezzini, A, Sangalli, D, Zedde, M, Pascarella, R, Ferrarese, C, Beretta, S, Diamanti, S, Schwarz, G, Frisullo, G, Marcheselli, S, Seners, P, Sabben, C, Escalard, S, Piotin, M, Maier, B, Charbonnier, G, Vuillier, F, Legris, L, Cuisenier, P, Vodret, F, Marnat, G, Liegey, J, Sibon, I, Flottmann, F, Broocks, G, Gloyer, N, Bohmann, F, Schaefer, J, Nolte, C, Audebert, H, Siebert, E, Sykora, M, Lang, W, Ferrari, J, Mayer-Suess, L, Knoflach, M, Gizewski, E, Stolp, J, Stolze, L, Coutinho, J, Nederkoorn, P, Van Den Wijngaard, I, De Meris, J, Lemmens, R, De Raedt, S, Vandervorst, F, Rutgers, M, Guilmot, A, Dusart, A, Bellante, F, Calleja-Castano, P, Ostos, F, Gonzalez-Ortega, G, Martin-Jimenez, P, Garcia-Madrona, S, Cruz-Culebras, A, Vera, R, Matute, M, Fuentes, B, Alonso-De-Lecinana, M, Rigual, R, Diez-Tejedor, E, Perez-Sanchez, S, Montaner, J, Diaz-Otero, F, Perez-De-La-Ossa, N, Flores-Pina, B, Munoz-Narbona, L, Chamorro, A, Rodriguez-Vazquez, A, Renu, A, Ayo-Martin, O, Hernandez-Fernandez, F, Segura, T, Tejada-Meza, H, Sagarra-Mur, D, Serrano-Ponz, M, Hlaing, T, See, I, Simister, R, Werring, D, Kristoffersen, E, Nordanstig, A, Jood, K, Rentzos, A, Simunek, L, Krajickova, D, Krajina, A, Mikulik, R, Cvikova, M, Vinklarek, J, Skoloudik, D, Roubec, M, Hurtikova, E, Hruby, R, Ostry, S, Skoda, O, Pernicka, M, Jurak, L, Eichlova, Z, Jira, M, Kovar, M, Pansky, M, Mencl, P, Palouskova, H, Tomek, A, Jansky, P, Olserova, A, Sramek, M, Havlicek, R, Maly, P, Trakal, L, Fiksa, J, Slovak, M, Karlinski, M, Nowak, M, Sienkiewicz-Jarosz, H, Bochynska, A, Wrona, P, Homa, T, Sawczynska, K, Slowik, A, Wlodarczyk, E, Wiacek, M, Tomaszewska-Lampart, I, Sieczkowski, B, Bartosik-Psujek, H, Bilik, M, Bandzarewicz, A, Dorobek, M, Zielinska-Turek, J, Nowakowska-Kotas, M, Obara, K, Urbanowski, P, Budrewicz, S, Guzinski, M, Switonska, M, Rutkowska, I, Sobieszak-Skura, P, Labuz-Roszak, B, Debiec, A, Staszewski, J, Stepien, A, Zwiernik, J, Wasilewski, G, Tiu, C, Terecoasa, E, Radu, R, Negrila, A, Dorobat, B, Panea, C, Tiu, V, Petrescu, S, Ozdemir, A, Mahmoud, M, El-Samahy, H, Abdelkhalek, H, Al-Hashel, J, Ismail, I, Salmeen, A, Ghoreishi, A, Sabetay, S, Gross, H, Klein, P, Abdalkader, M, Jabbour, P, El Naamani, K, Tjoumakaris, S, Abbas, R, Mohamed, G, Chebl, A, Min, J, Hovingh, M, Tsai, J, Khan, M, Nalleballe, K, Onteddu, S, Masoud, H, Michael, M, Kaur, N, Maali, L, Abraham, M, Khandelwal, P, Bach, I, Ong, M, Babici, D, Khawaja, A, Hakemi, M, Rajamani, K, Cano-Nigenda, V, Arauz, A, Amaya, P, Llanos, N, Arango, A, Vences, M, Barrientos Guerra, J, Caetano, R, Martins, R, Scollo, S, Yalung, P, Nagendra, S, Gaikwad, A, Seo, K, Georgiopoulos, G, Nogueira, R, Michel, P, Marto J. P., Strambo D., Ntaios G., Nguyen T. N., Herzig R., Czlonkowska A., Demeestere J., Mansour O. Y., Salerno A., Wegener S., Baumgartner P., Cereda C. W., Bianco G., Beyeler M., Arnold M., Carrera E., Machi P., Altersberger V., Bonati L., Gensicke H., Bolognese M., Peters N., Wetzel S., Magrico M., Ramos J. N., Sargento-Freitas J., Machado R., Maia C., Machado E., Nunes A. P., Ferreira P., Pinho E Melo T., Dias M. C., Paula A., Correia M. A., Castro P., Azevedo E., Albuquerque L., Alves J. N., Ferreira-Pinto J., Meira T., Pereira L., Rodrigues M., Araujo A. P., Rocha M., Pereira-Fonseca A., Ribeiro L., Varela R., Malheiro S., Cappellari M., Zivelonghi C., Sajeva G., Zini A., Gentile M., Forlivesi S., Migliaccio L., Sessa M., La Gioia S., Pezzini A., Sangalli D., Zedde M., Pascarella R., Ferrarese C., Beretta S., Diamanti S., Schwarz G., Frisullo G., Marcheselli S., Seners P., Sabben C., Escalard S., Piotin M., Maier B., Charbonnier G., Vuillier F., Legris L., Cuisenier P., Vodret F. R., Marnat G., Liegey J. -S., Sibon I., Flottmann F., Broocks G., Gloyer N. -O., Bohmann F. O., Schaefer J. H., Nolte C., Audebert H. J., Siebert E., Sykora M., Lang W., Ferrari J., Mayer-Suess L., Knoflach M., Gizewski E. R., Stolp J., Stolze L. J., Coutinho J. M., Nederkoorn P., Van Den Wijngaard I., De Meris J., Lemmens R., De Raedt S., Vandervorst F., Rutgers M. P., Guilmot A., Dusart A., Bellante F., Calleja-Castano P., Ostos F., Gonzalez-Ortega G., Martin-Jimenez P., Garcia-Madrona S., Cruz-Culebras A., Vera R., Matute M. C., Fuentes B., Alonso-De-Lecinana M., Rigual R., Diez-Tejedor E., Perez-Sanchez S., Montaner J., Diaz-Otero F., Perez-De-La-Ossa N., Flores-Pina B., Munoz-Narbona L., Chamorro A., Rodriguez-Vazquez A., Renu A., Ayo-Martin O., Hernandez-Fernandez F., Segura T., Tejada-Meza H., Sagarra-Mur D., Serrano-Ponz M., Hlaing T., See I., Simister R., Werring D., Kristoffersen E. S., Nordanstig A., Jood K., Rentzos A., Simunek L., Krajickova D., Krajina A., Mikulik R., Cvikova M., Vinklarek J., Skoloudik D., Roubec M., Hurtikova E., Hruby R., Ostry S., Skoda O., Pernicka M., Jurak L., Eichlova Z., Jira M., Kovar M., Pansky M., Mencl P., Palouskova H., Tomek A., Jansky P., Olserova A., Sramek M., Havlicek R., Maly P., Trakal L., Fiksa J., Slovak M., Karlinski M. A., Nowak M., Sienkiewicz-Jarosz H., Bochynska A., Wrona P., Homa T., Sawczynska K., Slowik A., Wlodarczyk E., Wiacek M., Tomaszewska-Lampart I., Sieczkowski B., Bartosik-Psujek H., Bilik M., Bandzarewicz A., Dorobek M., Zielinska-Turek J., Nowakowska-Kotas M., Obara K., Urbanowski P., Budrewicz S., Guzinski M., Switonska M., Rutkowska I., Sobieszak-Skura P., Labuz-Roszak B. M., Debiec A., Staszewski J., Stepien A., Zwiernik J., Wasilewski G., Tiu C., Terecoasa E. O., Radu R. A., Negrila A., Dorobat B., Panea C., Tiu V., Petrescu S., Ozdemir A., Mahmoud M., El-Samahy H., Abdelkhalek H., Al-Hashel J., Ismail I. I., Salmeen A., Ghoreishi A., Sabetay S. I., Gross H., Klein P., Abdalkader M., Jabbour P., El Naamani K., Tjoumakaris S., Abbas R., Mohamed G. A., Chebl A., Min J., Hovingh M., Tsai J. P., Khan M., Nalleballe K., Onteddu S., Masoud H., Michael M., Kaur N., Maali L., Abraham M. G., Khandelwal P., Bach I., Ong M., Babici D., Khawaja A. M., Hakemi M., Rajamani K., Cano-Nigenda V., Arauz A., Amaya P., Llanos N., Arango A., Vences M. A., Barrientos Guerra J. D., Caetano R., Martins R. T., Scollo S. D., Yalung P. M., Nagendra S., Gaikwad A., Seo K. -D., Georgiopoulos G., Nogueira R. G., Michel P., Marto, J, Strambo, D, Ntaios, G, Nguyen, T, Herzig, R, Czlonkowska, A, Demeestere, J, Mansour, O, Salerno, A, Wegener, S, Baumgartner, P, Cereda, C, Bianco, G, Beyeler, M, Arnold, M, Carrera, E, Machi, P, Altersberger, V, Bonati, L, Gensicke, H, Bolognese, M, Peters, N, Wetzel, S, Magrico, M, Ramos, J, Sargento-Freitas, J, Machado, R, Maia, C, Machado, E, Nunes, A, Ferreira, P, Pinho E Melo, T, Dias, M, Paula, A, Correia, M, Castro, P, Azevedo, E, Albuquerque, L, Alves, J, Ferreira-Pinto, J, Meira, T, Pereira, L, Rodrigues, M, Araujo, A, Rocha, M, Pereira-Fonseca, A, Ribeiro, L, Varela, R, Malheiro, S, Cappellari, M, Zivelonghi, C, Sajeva, G, Zini, A, Gentile, M, Forlivesi, S, Migliaccio, L, Sessa, M, La Gioia, S, Pezzini, A, Sangalli, D, Zedde, M, Pascarella, R, Ferrarese, C, Beretta, S, Diamanti, S, Schwarz, G, Frisullo, G, Marcheselli, S, Seners, P, Sabben, C, Escalard, S, Piotin, M, Maier, B, Charbonnier, G, Vuillier, F, Legris, L, Cuisenier, P, Vodret, F, Marnat, G, Liegey, J, Sibon, I, Flottmann, F, Broocks, G, Gloyer, N, Bohmann, F, Schaefer, J, Nolte, C, Audebert, H, Siebert, E, Sykora, M, Lang, W, Ferrari, J, Mayer-Suess, L, Knoflach, M, Gizewski, E, Stolp, J, Stolze, L, Coutinho, J, Nederkoorn, P, Van Den Wijngaard, I, De Meris, J, Lemmens, R, De Raedt, S, Vandervorst, F, Rutgers, M, Guilmot, A, Dusart, A, Bellante, F, Calleja-Castano, P, Ostos, F, Gonzalez-Ortega, G, Martin-Jimenez, P, Garcia-Madrona, S, Cruz-Culebras, A, Vera, R, Matute, M, Fuentes, B, Alonso-De-Lecinana, M, Rigual, R, Diez-Tejedor, E, Perez-Sanchez, S, Montaner, J, Diaz-Otero, F, Perez-De-La-Ossa, N, Flores-Pina, B, Munoz-Narbona, L, Chamorro, A, Rodriguez-Vazquez, A, Renu, A, Ayo-Martin, O, Hernandez-Fernandez, F, Segura, T, Tejada-Meza, H, Sagarra-Mur, D, Serrano-Ponz, M, Hlaing, T, See, I, Simister, R, Werring, D, Kristoffersen, E, Nordanstig, A, Jood, K, Rentzos, A, Simunek, L, Krajickova, D, Krajina, A, Mikulik, R, Cvikova, M, Vinklarek, J, Skoloudik, D, Roubec, M, Hurtikova, E, Hruby, R, Ostry, S, Skoda, O, Pernicka, M, Jurak, L, Eichlova, Z, Jira, M, Kovar, M, Pansky, M, Mencl, P, Palouskova, H, Tomek, A, Jansky, P, Olserova, A, Sramek, M, Havlicek, R, Maly, P, Trakal, L, Fiksa, J, Slovak, M, Karlinski, M, Nowak, M, Sienkiewicz-Jarosz, H, Bochynska, A, Wrona, P, Homa, T, Sawczynska, K, Slowik, A, Wlodarczyk, E, Wiacek, M, Tomaszewska-Lampart, I, Sieczkowski, B, Bartosik-Psujek, H, Bilik, M, Bandzarewicz, A, Dorobek, M, Zielinska-Turek, J, Nowakowska-Kotas, M, Obara, K, Urbanowski, P, Budrewicz, S, Guzinski, M, Switonska, M, Rutkowska, I, Sobieszak-Skura, P, Labuz-Roszak, B, Debiec, A, Staszewski, J, Stepien, A, Zwiernik, J, Wasilewski, G, Tiu, C, Terecoasa, E, Radu, R, Negrila, A, Dorobat, B, Panea, C, Tiu, V, Petrescu, S, Ozdemir, A, Mahmoud, M, El-Samahy, H, Abdelkhalek, H, Al-Hashel, J, Ismail, I, Salmeen, A, Ghoreishi, A, Sabetay, S, Gross, H, Klein, P, Abdalkader, M, Jabbour, P, El Naamani, K, Tjoumakaris, S, Abbas, R, Mohamed, G, Chebl, A, Min, J, Hovingh, M, Tsai, J, Khan, M, Nalleballe, K, Onteddu, S, Masoud, H, Michael, M, Kaur, N, Maali, L, Abraham, M, Khandelwal, P, Bach, I, Ong, M, Babici, D, Khawaja, A, Hakemi, M, Rajamani, K, Cano-Nigenda, V, Arauz, A, Amaya, P, Llanos, N, Arango, A, Vences, M, Barrientos Guerra, J, Caetano, R, Martins, R, Scollo, S, Yalung, P, Nagendra, S, Gaikwad, A, Seo, K, Georgiopoulos, G, Nogueira, R, Michel, P, Marto J. P., Strambo D., Ntaios G., Nguyen T. N., Herzig R., Czlonkowska A., Demeestere J., Mansour O. Y., Salerno A., Wegener S., Baumgartner P., Cereda C. W., Bianco G., Beyeler M., Arnold M., Carrera E., Machi P., Altersberger V., Bonati L., Gensicke H., Bolognese M., Peters N., Wetzel S., Magrico M., Ramos J. N., Sargento-Freitas J., Machado R., Maia C., Machado E., Nunes A. P., Ferreira P., Pinho E Melo T., Dias M. C., Paula A., Correia M. A., Castro P., Azevedo E., Albuquerque L., Alves J. N., Ferreira-Pinto J., Meira T., Pereira L., Rodrigues M., Araujo A. P., Rocha M., Pereira-Fonseca A., Ribeiro L., Varela R., Malheiro S., Cappellari M., Zivelonghi C., Sajeva G., Zini A., Gentile M., Forlivesi S., Migliaccio L., Sessa M., La Gioia S., Pezzini A., Sangalli D., Zedde M., Pascarella R., Ferrarese C., Beretta S., Diamanti S., Schwarz G., Frisullo G., Marcheselli S., Seners P., Sabben C., Escalard S., Piotin M., Maier B., Charbonnier G., Vuillier F., Legris L., Cuisenier P., Vodret F. R., Marnat G., Liegey J. -S., Sibon I., Flottmann F., Broocks G., Gloyer N. -O., Bohmann F. O., Schaefer J. H., Nolte C., Audebert H. J., Siebert E., Sykora M., Lang W., Ferrari J., Mayer-Suess L., Knoflach M., Gizewski E. R., Stolp J., Stolze L. J., Coutinho J. M., Nederkoorn P., Van Den Wijngaard I., De Meris J., Lemmens R., De Raedt S., Vandervorst F., Rutgers M. P., Guilmot A., Dusart A., Bellante F., Calleja-Castano P., Ostos F., Gonzalez-Ortega G., Martin-Jimenez P., Garcia-Madrona S., Cruz-Culebras A., Vera R., Matute M. C., Fuentes B., Alonso-De-Lecinana M., Rigual R., Diez-Tejedor E., Perez-Sanchez S., Montaner J., Diaz-Otero F., Perez-De-La-Ossa N., Flores-Pina B., Munoz-Narbona L., Chamorro A., Rodriguez-Vazquez A., Renu A., Ayo-Martin O., Hernandez-Fernandez F., Segura T., Tejada-Meza H., Sagarra-Mur D., Serrano-Ponz M., Hlaing T., See I., Simister R., Werring D., Kristoffersen E. S., Nordanstig A., Jood K., Rentzos A., Simunek L., Krajickova D., Krajina A., Mikulik R., Cvikova M., Vinklarek J., Skoloudik D., Roubec M., Hurtikova E., Hruby R., Ostry S., Skoda O., Pernicka M., Jurak L., Eichlova Z., Jira M., Kovar M., Pansky M., Mencl P., Palouskova H., Tomek A., Jansky P., Olserova A., Sramek M., Havlicek R., Maly P., Trakal L., Fiksa J., Slovak M., Karlinski M. A., Nowak M., Sienkiewicz-Jarosz H., Bochynska A., Wrona P., Homa T., Sawczynska K., Slowik A., Wlodarczyk E., Wiacek M., Tomaszewska-Lampart I., Sieczkowski B., Bartosik-Psujek H., Bilik M., Bandzarewicz A., Dorobek M., Zielinska-Turek J., Nowakowska-Kotas M., Obara K., Urbanowski P., Budrewicz S., Guzinski M., Switonska M., Rutkowska I., Sobieszak-Skura P., Labuz-Roszak B. M., Debiec A., Staszewski J., Stepien A., Zwiernik J., Wasilewski G., Tiu C., Terecoasa E. O., Radu R. A., Negrila A., Dorobat B., Panea C., Tiu V., Petrescu S., Ozdemir A., Mahmoud M., El-Samahy H., Abdelkhalek H., Al-Hashel J., Ismail I. I., Salmeen A., Ghoreishi A., Sabetay S. I., Gross H., Klein P., Abdalkader M., Jabbour P., El Naamani K., Tjoumakaris S., Abbas R., Mohamed G. A., Chebl A., Min J., Hovingh M., Tsai J. P., Khan M., Nalleballe K., Onteddu S., Masoud H., Michael M., Kaur N., Maali L., Abraham M. G., Khandelwal P., Bach I., Ong M., Babici D., Khawaja A. M., Hakemi M., Rajamani K., Cano-Nigenda V., Arauz A., Amaya P., Llanos N., Arango A., Vences M. A., Barrientos Guerra J. D., Caetano R., Martins R. T., Scollo S. D., Yalung P. M., Nagendra S., Gaikwad A., Seo K. -D., Georgiopoulos G., Nogueira R. G., and Michel P.

Abstract

Background and Objectives COVID-19–related inflammation, endothelial dysfunction, and coagulopathy may increase the bleeding risk and lower the efficacy of revascularization treatments in patients with acute ischemic stroke (AIS). We aimed to evaluate the safety and outcomes of revascularization treatments in patients with AIS and COVID-19. Methods This was a retrospective multicenter cohort study of consecutive patients with AIS receiving intravenous thrombolysis (IVT) and/or endovascular treatment (EVT) between March 2020 and June 2021 tested for severe acute respiratory syndrome coronavirus 2 infection. With a doubly robust model combining propensity score weighting and multivariate regression, we studied the association of COVID-19 with intracranial bleeding complications and clinical outcomes. Subgroup analyses were performed according to treatment groups (IVT-only and EVT). Results Of a total of 15,128 included patients from 105 centers, 853 (5.6%) were diagnosed with COVID-19; of those, 5,848 (38.7%) patients received IVT-only and 9,280 (61.3%) EVT (with or without IVT). Patients with COVID-19 had a higher rate of symptomatic intracerebral hemorrhage (SICH) (adjusted OR 1.53; 95% CI 1.16–2.01), symptomatic subarachnoid hemorrhage (SSAH) (OR 1.80; 95% CI 1.20–2.69), SICH and/or SSAH combined (OR 1.56; 95% CI 1.23–1.99), 24-hour mortality (OR 2.47; 95% CI 1.58–3.86), and 3-month mortality (OR 1.88; 95% CI 1.52–2.33). Patients with COVID-19 also had an unfavorable shift in the distribution of the modified Rankin score at 3 months (OR 1.42; 95% CI 1.26–1.60). Discussion Patients with AIS and COVID-19 showed higher rates of intracranial bleeding complications and worse clinical outcomes after revascularization treatments than contemporaneous non–COVID-19 patients receiving treatment. Current available data do not allow direct conclusions to be drawn on the effectiveness of revascularization treatments in patients with COVID-19 or to establish different treatment r

Published
2023

7. Plasma levels of amyloid beta 1-40 are associated with ultrasonographic morphological characteristics related with carotid plaque vulnerability in individuals without cardiovascular disease

Author

Delialis, D I M I T R, primary, Angelidakis, L, additional, Georgiopoulos, G, additional, Aivalioti, E, additional, Mavraganis, G, additional, Tual-Chalot, S, additional, Sopova, K, additional, Bampatsias, D, additional, Maneta, E, additional, Dimopouou, A M, additional, Patras, R, additional, Konstantaki, C, additional, Papaioannou, M, additional, Stellos, K, additional, and Stamatelopoulos, K, additional

Published
2023
Full Text
View/download PDF

9. Remnant cholesterol in atherosclerotic cardiovascular disease: a systematic review and meta-analysis

Author

Delialis, D D, primary, Georgiopoulos, G G, additional, Aivalioti, E A, additional, Konstantaki, C K, additional, Oikonomou, E O, additional, Bampatsias, D B, additional, Mavraganis, G M, additional, Maneta, E M, additional, Patras, R P, additional, Papaioannou, M P, additional, Dimopoulou, A M D, additional, Angelidakis, L A, additional, Liberopoulos, E L, additional, Stellos, K S, additional, and Stamatelopoulos, K, additional

Published
2023
Full Text
View/download PDF

10. Circulating amyloid-beta 1-40 levels associate with cardiac remodelling and myocardial recovery in advanced heart failure

Author

Stamatelopoulos, K, primary, Bampatsias, D, additional, Kyriakopoulos, C, additional, Sopova, K, additional, Georgiopoulos, G, additional, Hamouche, R, additional, Shankar, T, additional, Tseliou, E, additional, Bonios, M, additional, Tual-Chalot, S, additional, Kyriazis, I, additional, Selzaman, C, additional, Drosatos, K, additional, Stellos, K, additional, and Drakos, S, additional

Published
2023
Full Text
View/download PDF

11. The effect of tafamidis treatment on cardiovascular aging in patients with Transthyretin cardiomyopathy. An observational study

Author

Bampatsias, D, primary, Georgiopoulos, G, additional, Delialis, D, additional, Angelidakis, L, additional, Theodorakakou, F, additional, Petropoulos, I, additional, Tselegkidi, M E, additional, Zervas, G, additional, Dimoula, A, additional, Patras, R, additional, Kyriazopoulou, A, additional, Trougakos, I, additional, Briasoulis, A, additional, Kastritis, E, additional, and Stamatelopoulos, K, additional

Published
2023
Full Text
View/download PDF

18. RNA-binding protein HuR controls vascular endothelial cell inflammatory responses to tumor necrosis factor-A and is associated with atherosclerosis progression in humans

Author

Sachse, M., primary, Georgiopoulos, G., additional, Tual-Chalot, S., additional, Sopova, K., additional, Polycarpou-Schwarz, M., additional, Amponsah-Offeh, M., additional, Ciliberti, G., additional, Bonini, F., additional, Mavraganis, G., additional, Bampatsias, D., additional, Delialis, D., additional, Gatsiou, A., additional, Stamatelopoulos, K., additional, and Stellos, K., additional

Published
2023
Full Text
View/download PDF

20. Development and validation of a dementia risk score in the UK Biobank and Whitehall II Cohorts

Author

Anatürk, M., Patel, R., Ebmeier, K.P., Georgiopoulos, G., Newby, D., Topiwala, A., Lange, A.M.G. de, Cole, J.H., Jansen, M.G., Singh-Manoux, A., Kivimäki, M., Suri, S., Anatürk, M., Patel, R., Ebmeier, K.P., Georgiopoulos, G., Newby, D., Topiwala, A., Lange, A.M.G. de, Cole, J.H., Jansen, M.G., Singh-Manoux, A., Kivimäki, M., and Suri, S.

Abstract

Contains fulltext : 295505.pdf (Publisher’s version ) (Open Access), Background: Current dementia risk scores have had limited success in consistently identifying at-risk individuals across different ages and geographical locations. Objective: We aimed to develop and validate a novel dementia risk score for a midlife UK population, using two cohorts: the UK Biobank, and UK Whitehall II study. Methods: We divided the UK Biobank cohort into a training (n=176 611, 80%) and test sample (n=44 151, 20%) and used the Whitehall II cohort (n=2934) for external validation. We used the Cox LASSO regression to select the strongest predictors of incident dementia from 28 candidate predictors and then developed the risk score using competing risk regression. Findings: Our risk score, termed the UK Biobank Dementia Risk Score (UKBDRS), consisted of age, education, parental history of dementia, material deprivation, a history of diabetes, stroke, depression, hypertension, high cholesterol, household occupancy, and sex. The score had a strong discrimination accuracy in the UK Biobank test sample (area under the curve (AUC) 0.8, 95% CI 0.78 to 0.82) and in the Whitehall cohort (AUC 0.77, 95% CI 0.72 to 0.81). The UKBDRS also significantly outperformed three other widely used dementia risk scores originally developed in cohorts in Australia (the Australian National University Alzheimer’s Disease Risk Index), Finland (the Cardiovascular Risk Factors, Ageing, and Dementia score), and the UK (Dementia Risk Score). Clinical implications: Our risk score represents an easy-to-use tool to identify individuals at risk for dementia in the UK. Further research is required to determine the validity of this score in other populations.

Published
2023

21. The importance of microvascular inflammation in ageing and age-related diseases: a position paper from the ESH working group on small arteries, section of microvascular inflammation

Author

Mengozzi, A, de Ciuceis, C, Dell'Oro, R, Georgiopoulos, G, Lazaridis, A, Nosalski, R, Pavlidis, G, Tual-Chalot, S, Agabiti-Rosei, C, Anyfanti, P, Camargo, L, Dąbrowska, E, Quarti-Trevano, F, Hellmann, M, Masi, S, Mavraganis, G, Montezano, A, Rios, F, Winklewski, P, Wolf, J, Costantino, S, Gkaliagkousi, E, Grassi, G, Guzik, T, Ikonomidis, I, Narkiewicz, K, Paneni, F, Rizzoni, D, Stamatelopoulos, K, Stellos, K, Taddei, S, Touyz, R, Triantafyllou, A, Virdis, A, Mengozzi, Alessandro, de Ciuceis, Carolina, Dell'oro, Raffaella, Georgiopoulos, Georgios, Lazaridis, Antonios, Nosalski, Ryszard, Pavlidis, George, Tual-Chalot, Simon, Agabiti-Rosei, Claudia, Anyfanti, Panagiota, Camargo, Livia L, Dąbrowska, Edyta, Quarti-Trevano, Fosca, Hellmann, Marcin, Masi, Stefano, Mavraganis, Georgios, Montezano, Augusto C, Rios, Francesco J, Winklewski, Pawel J, Wolf, Jacek, Costantino, Sarah, Gkaliagkousi, Eugenia, Grassi, Guido, Guzik, Tomasz J, Ikonomidis, Ignatios, Narkiewicz, Krzysztof, Paneni, Francesco, Rizzoni, Damiano, Stamatelopoulos, Kimon, Stellos, Konstantinos, Taddei, Stefano, Touyz, Rhian M, Triantafyllou, Areti, Virdis, Agostino, Mengozzi, A, de Ciuceis, C, Dell'Oro, R, Georgiopoulos, G, Lazaridis, A, Nosalski, R, Pavlidis, G, Tual-Chalot, S, Agabiti-Rosei, C, Anyfanti, P, Camargo, L, Dąbrowska, E, Quarti-Trevano, F, Hellmann, M, Masi, S, Mavraganis, G, Montezano, A, Rios, F, Winklewski, P, Wolf, J, Costantino, S, Gkaliagkousi, E, Grassi, G, Guzik, T, Ikonomidis, I, Narkiewicz, K, Paneni, F, Rizzoni, D, Stamatelopoulos, K, Stellos, K, Taddei, S, Touyz, R, Triantafyllou, A, Virdis, A, Mengozzi, Alessandro, de Ciuceis, Carolina, Dell'oro, Raffaella, Georgiopoulos, Georgios, Lazaridis, Antonios, Nosalski, Ryszard, Pavlidis, George, Tual-Chalot, Simon, Agabiti-Rosei, Claudia, Anyfanti, Panagiota, Camargo, Livia L, Dąbrowska, Edyta, Quarti-Trevano, Fosca, Hellmann, Marcin, Masi, Stefano, Mavraganis, Georgios, Montezano, Augusto C, Rios, Francesco J, Winklewski, Pawel J, Wolf, Jacek, Costantino, Sarah, Gkaliagkousi, Eugenia, Grassi, Guido, Guzik, Tomasz J, Ikonomidis, Ignatios, Narkiewicz, Krzysztof, Paneni, Francesco, Rizzoni, Damiano, Stamatelopoulos, Kimon, Stellos, Konstantinos, Taddei, Stefano, Touyz, Rhian M, Triantafyllou, Areti, and Virdis, Agostino

Abstract

Microcirculation is pervasive and orchestrates a profound regulatory cross-talk with the surrounding tissue and organs. Similarly, it is one of the earliest biological systems targeted by environmental stressors and consequently involved in the development and progression of ageing and age-related disease. Microvascular dysfunction, if not targeted, leads to a steady derangement of the phenotype, which cumulates comorbidities and eventually results in a nonrescuable, very high-cardiovascular risk. Along the broad spectrum of pathologies, both shared and distinct molecular pathways and pathophysiological alteration are involved in the disruption of microvascular homeostasis, all pointing to microvascular inflammation as the putative primary culprit. This position paper explores the presence and the detrimental contribution of microvascular inflammation across the whole spectrum of chronic age-related diseases, which characterise the 21st-century healthcare landscape. The manuscript aims to strongly affirm the centrality of microvascular inflammation by recapitulating the current evidence and providing a clear synoptic view of the whole cardiometabolic derangement. Indeed, there is an urgent need for further mechanistic exploration to identify clear, very early or disease-specific molecular targets to provide an effective therapeutic strategy against the otherwise unstoppable rising prevalence of age-related diseases.

Published
2023

22. Myocardial Fibrosis at Cardiac MRI Helps Predict Adverse Clinical Outcome in Patients with Mitral Valve Prolapse

Author

Figliozzi, S, Georgiopoulos, G, Lopes, P, Bauer, K, Moura-Ferreira, S, Tondi, L, Mushtaq, S, Censi, S, Pavon, A, Bassi, I, Servato, M, Teske, A, Biondi, F, Filomena, D, Pica, S, Torlasco, C, Muraru, D, Monney, P, Quattrocchi, G, Maestrini, V, Agati, L, Monti, L, Pedrotti, P, Vandenberk, B, Squeri, A, Lombardi, M, Ferreira, A, Schwitter, J, Aquaro, G, Chiribiri, A, Rodríguez Palomares, J, Yilmaz, A, Andreini, D, Florian, A, Leiner, T, Abecasis, J, Badano, L, Bogaert, J, Masci, P, Figliozzi, Stefano, Georgiopoulos, Georgios, Lopes, Pedro M, Bauer, Klemens B, Moura-Ferreira, Sara, Tondi, Lara, Mushtaq, Saima, Censi, Stefano, Pavon, Anna Giulia, Bassi, Ilaria, Servato, Maria Luz, Teske, Arco J, Biondi, Federico, Filomena, Domenico, Pica, Silvia, Torlasco, Camilla, Muraru, Denisa, Monney, Pierre, Quattrocchi, Giuseppina, Maestrini, Viviana, Agati, Luciano, Monti, Lorenzo, Pedrotti, Patrizia, Vandenberk, Bert, Squeri, Angelo, Lombardi, Massimo, Ferreira, António M, Schwitter, Juerg, Aquaro, Giovanni Donato, Chiribiri, Amedeo, Rodríguez Palomares, José F, Yilmaz, Ali, Andreini, Daniele, Florian, Anca, Leiner, Tim, Abecasis, João, Badano, Luigi, Bogaert, Jan, Masci, Pier-Giorgio, Figliozzi, S, Georgiopoulos, G, Lopes, P, Bauer, K, Moura-Ferreira, S, Tondi, L, Mushtaq, S, Censi, S, Pavon, A, Bassi, I, Servato, M, Teske, A, Biondi, F, Filomena, D, Pica, S, Torlasco, C, Muraru, D, Monney, P, Quattrocchi, G, Maestrini, V, Agati, L, Monti, L, Pedrotti, P, Vandenberk, B, Squeri, A, Lombardi, M, Ferreira, A, Schwitter, J, Aquaro, G, Chiribiri, A, Rodríguez Palomares, J, Yilmaz, A, Andreini, D, Florian, A, Leiner, T, Abecasis, J, Badano, L, Bogaert, J, Masci, P, Figliozzi, Stefano, Georgiopoulos, Georgios, Lopes, Pedro M, Bauer, Klemens B, Moura-Ferreira, Sara, Tondi, Lara, Mushtaq, Saima, Censi, Stefano, Pavon, Anna Giulia, Bassi, Ilaria, Servato, Maria Luz, Teske, Arco J, Biondi, Federico, Filomena, Domenico, Pica, Silvia, Torlasco, Camilla, Muraru, Denisa, Monney, Pierre, Quattrocchi, Giuseppina, Maestrini, Viviana, Agati, Luciano, Monti, Lorenzo, Pedrotti, Patrizia, Vandenberk, Bert, Squeri, Angelo, Lombardi, Massimo, Ferreira, António M, Schwitter, Juerg, Aquaro, Giovanni Donato, Chiribiri, Amedeo, Rodríguez Palomares, José F, Yilmaz, Ali, Andreini, Daniele, Florian, Anca, Leiner, Tim, Abecasis, João, Badano, Luigi, Bogaert, Jan, and Masci, Pier-Giorgio

Abstract

Background: Patients with mitral valve prolapse (MVP) may develop adverse outcomes even in the absence of mitral regurgitation or left ventricular (LV) dysfunction. Purpose: To investigate the prognostic value of mitral annulus disjunction (MAD) and myocardial fibrosis at late gadolinium enhancement (LGE) cardiac MRI in patients with MVP without moderate-to-severe mitral regurgitation or LV dysfunction. Materials and Methods: In this longitudinal retrospective study, 118 144 cardiac MRI studies were evaluated between October 2007 and June 2020 at 15 European tertiary medical centers. Follow-up was from the date of cardiac MRI examination to June 2020; the minimum and maximum follow-up intervals were 6 months and 156 months, respectively. Patients were excluded if at least one of the following conditions was present: cardiomyopathy, LV ejection fraction less than 40%, ischemic heart disease, congenital heart disease, inflammatory heart disease, moderate or worse mitral regurgitation, participation in competitive sport, or electrocardiogram suggestive of channelopathies. In the remainder, cardiac MRI studies were reanalyzed, and patients were included if they were aged 18 years or older, MVP was diagnosed at cardiac MRI, and clinical information and electrocardiogram monitoring were available within 3 months from cardiac MRI examination. The end point was a composite of adverse outcomes: sustained ventricular tachycardia (VT), sudden cardiac death (SCD), or unexplained syncope. Multivariable Cox regression analysis was performed. Results: A total of 474 patients (mean age, 47 years ± 16 [SD]; 244 women) were included. Over a median follow-up of 3.3 years, 18 patients (4%) reached the study end point. LGE presence (hazard ratio, 4.2 [95% CI: 1.5, 11.9]; P = .006) and extent (hazard ratio, 1.2 per 1% increase [95% CI: 1.1, 1.4]; P = .006), but not MAD presence (P = .89), were associated with clinical outcome. LGE presence had incremental prognostic value over MVP severi

Published
2023

23. Corrigendum to: High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid

Author

Palatini, P, Palatini, P, Parati, G, Virdis, A, Reboldi, G, Masi, S, Mengozzi, A, Casiglia, E, Tikhonoff, V, Cicero, A, Ungar, A, Rivasi, G, Salvetti, M, Barbagallo, C, Bombelli, M, Dell'Oro, R, Bruno, B, Lippa, L, D'Elia, L, Verdecchia, P, Angeli, F, Mallamaci, F, Cirillo, M, Rattazzi, M, Cirillo, P, Gesualdo, L, Mazza, A, Giannattasio, C, Maloberti, A, Volpe, M, Tocci, G, Georgiopoulos, G, Iaccarino, G, Nazzaro, P, Galletti, F, Ferri, C, Desideri, G, Viazzi, F, Pontremoli, R, Muiesan, M, Grassi, G, Borghi, C, Cicero, AFG, Barbagallo, CM, Muiesan, ML, Palatini, P, Palatini, P, Parati, G, Virdis, A, Reboldi, G, Masi, S, Mengozzi, A, Casiglia, E, Tikhonoff, V, Cicero, A, Ungar, A, Rivasi, G, Salvetti, M, Barbagallo, C, Bombelli, M, Dell'Oro, R, Bruno, B, Lippa, L, D'Elia, L, Verdecchia, P, Angeli, F, Mallamaci, F, Cirillo, M, Rattazzi, M, Cirillo, P, Gesualdo, L, Mazza, A, Giannattasio, C, Maloberti, A, Volpe, M, Tocci, G, Georgiopoulos, G, Iaccarino, G, Nazzaro, P, Galletti, F, Ferri, C, Desideri, G, Viazzi, F, Pontremoli, R, Muiesan, M, Grassi, G, Borghi, C, Cicero, AFG, Barbagallo, CM, and Muiesan, ML

Published
2023

24. Three‐dimensional echocardiography and strain cardiac imaging in women with pre‐eclampsia with follow‐up to 6 months postpartum.

Author

Company Calabuig, A. M., Nunez, E., Georgiopoulos, G., Nicolaides, K. H., Charakida, M., and De Paco Matallana, C.

Subjects
LEFT ventricular hypertrophy, GLOBAL longitudinal strain, CARDIAC imaging, PREECLAMPSIA, PUERPERIUM, ECHOCARDIOGRAPHY
Abstract

Objective: Epidemiological studies have established that women with pre‐eclampsia (PE) are at increased long‐term cardiovascular risk. Mild cardiac functional changes have been documented during pregnancy in women with PE, but their evolution from presentation to the postpartum period remains poorly defined. The aim of this study was to assess biventricular cardiovascular indices using novel and sensitive two‐dimensional and three‐dimensional (3D) echocardiographic modalities in pregnancy and to track alterations in both risk factors and cardiovascular indices in the postpartum period. Methods: A total of 59 women with PE were examined at 34 (interquartile range, 31–37) weeks' gestation and at 2–3 days, 3 months and 6 months postpartum. During pregnancy, 118 women with a normotensive pregnancy were also recruited as controls. Biventricular ejection fraction and left ventricular mass were measured by 3D echocardiography. Biventricular global longitudinal strain and strain of the left atrium were assessed using speckle‐tracking imaging. Results: In women with PE, compared with controls, there was lower left ventricular diastolic function (left atrial reservoir strain, 44.1% vs 49.2%) and increased left ventricular mass index (148 vs 128 g/m2), but there was no significant difference in right ventricular functional indices. These alterations in cardiac indices were mostly explained by differences in maternal risk factors. In the postpartum period, most cardiac indices improved by 3 months. Multivariable linear mixed‐model analysis demonstrated that this improvement was mostly attributed to reduction in weight and blood pressure. Conclusion: In women with PE, there is postpartum improvement in cardiac functional and structural indices in parallel with improvement in their risk factor profile. © 2023 International Society of Ultrasound in Obstetrics and Gynecology. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

29. The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk

Author

Pugliese, N, Mengozzi, A, Virdis, A, Casiglia, E, Tikhonoff, V, Cicero, A, Ungar, A, Rivasi, G, Salvetti, M, Barbagallo, C, Bombelli, M, Dell'Oro, R, Bruno, B, Lippa, L, D'Elia, L, Verdecchia, P, Mallamaci, F, Cirillo, M, Rattazzi, M, Cirillo, P, Gesualdo, L, Mazza, A, Giannattasio, C, Maloberti, A, Volpe, M, Tocci, G, Georgiopoulos, G, Iaccarino, G, Nazzaro, P, Parati, G, Palatini, P, Galletti, F, Ferri, C, Desideri, G, Viazzi, F, Pontremoli, R, Muiesan, M, Grassi, G, Masi, S, Borghi, C, Pugliese N. R., Mengozzi A., Virdis A., Casiglia E., Tikhonoff V., Cicero A. F. G., Ungar A., Rivasi G., Salvetti M., Barbagallo C. M., Bombelli M., Dell'Oro R., Bruno B., Lippa L., D'Elia L., Verdecchia P., Mallamaci F., Cirillo M., Rattazzi M., Cirillo P., Gesualdo L., Mazza A., Giannattasio C., Maloberti A., Volpe M., Tocci G., Georgiopoulos G., Iaccarino G., Nazzaro P., Parati G., Palatini P., Galletti F., Ferri C., Desideri G., Viazzi F., Pontremoli R., Muiesan M. L., Grassi G., Masi S., Borghi C., Pugliese, N, Mengozzi, A, Virdis, A, Casiglia, E, Tikhonoff, V, Cicero, A, Ungar, A, Rivasi, G, Salvetti, M, Barbagallo, C, Bombelli, M, Dell'Oro, R, Bruno, B, Lippa, L, D'Elia, L, Verdecchia, P, Mallamaci, F, Cirillo, M, Rattazzi, M, Cirillo, P, Gesualdo, L, Mazza, A, Giannattasio, C, Maloberti, A, Volpe, M, Tocci, G, Georgiopoulos, G, Iaccarino, G, Nazzaro, P, Parati, G, Palatini, P, Galletti, F, Ferri, C, Desideri, G, Viazzi, F, Pontremoli, R, Muiesan, M, Grassi, G, Masi, S, Borghi, C, Pugliese N. R., Mengozzi A., Virdis A., Casiglia E., Tikhonoff V., Cicero A. F. G., Ungar A., Rivasi G., Salvetti M., Barbagallo C. M., Bombelli M., Dell'Oro R., Bruno B., Lippa L., D'Elia L., Verdecchia P., Mallamaci F., Cirillo M., Rattazzi M., Cirillo P., Gesualdo L., Mazza A., Giannattasio C., Maloberti A., Volpe M., Tocci G., Georgiopoulos G., Iaccarino G., Nazzaro P., Parati G., Palatini P., Galletti F., Ferri C., Desideri G., Viazzi F., Pontremoli R., Muiesan M. L., Grassi G., Masi S., and Borghi C.

Abstract

Introduction: Serum uric acid (SUA) has been depicted as a contributory causal factor in metabolic syndrome (MS), which in turn, portends unfavourable prognosis. Aim: We assessed the prognostic role of SUA in patients with and without MS. Methods: We used data from the multicentre Uric Acid Right for Heart Health study and considered cardiovascular mortality (CVM) as death due to fatal myocardial infarction, stroke, sudden cardiac death, or heart failure. Results: A total of 9589 subjects (median age 58.5 years, 45% males) were included in the analysis, and 5100 (53%) patients had a final diagnosis of MS. After a median follow-up of 142 months, we observed 558 events. Using a previously validated cardiovascular SUA cut-off to predict CVM (> 5.1 mg/dL in women and 5.6 mg/dL in men), elevated SUA levels were significantly associated to a worse outcome in patients with and without MS (all p < 0.0001) and provided a significant net reclassification improvement of 7.1% over the diagnosis of MS for CVM (p = 0.004). Cox regression analyses identified an independent association between SUA and CVM (Hazard Ratio: 1.79 [95% CI, 1.15–2.79]; p < 0.0001) after the adjustment for MS, its single components and renal function. Three specific combinations of the MS components were associated with higher CVM when increasing SUA levels were reported, and systemic hypertension was the only individual component ever-present (all p < 0.0001). Conclusion: Increasing SUA levels are associated with a higher CVM risk irrespective of the presence of MS: a cardiovascular SUA threshold may improve risk stratification. Graphic abstract: [Figure not available: see fulltext.]

Published
2021

31. Protective effect of N-acetyl cysteine on vascular function of young individuals after a bout of resistance exercise: a randomized placebo-controlled study

Author

Mavraganis, G, primary, Georgiopoulos, G, additional, Sakelliou, A, additional, Delialis, D, additional, Patras, R, additional, Sianis, A, additional, Dimopoulou, A M, additional, Oikonomou, E, additional, Athanasopoulos, S, additional, Kanakakis, I, additional, Fatouros, I, additional, Mitrakou, A, additional, and Stamatelopoulos, K, additional

Published
2022
Full Text
View/download PDF

32. Sustained vasodilation after cold pressor test is an independent predictor of poor survival in primary AL amyloidosis

Author

Patras, R, primary, Georgiopoulos, G, additional, Petropoulos, I, additional, Theodorakakou, F, additional, Delialis, D, additional, Angelidakis, L, additional, Gavriatopoulou, M, additional, Dimopoulou, M A, additional, Sianis, A, additional, Maneta, E, additional, Neofytou, O, additional, Terpos, E, additional, Dimopoulos, M A, additional, Kastritis, E, additional, and Stamatelopoulos, K, additional

Published
2022
Full Text
View/download PDF

33. Carotid ultrasonography improves residual risk stratification in guidelines-defined high cardiovascular risk patients

Author

Mavraganis, G, primary, Georgiopoulos, G, additional, Delialis, D, additional, Aivalioti, E, additional, Patras, R, additional, Petropoulos, I, additional, Dimopoulou, A M, additional, Angelidakis, L, additional, Sianis, A, additional, Bampatsias, D, additional, Dimoula, A, additional, Maneta, E, additional, Kosmopoulos, M, additional, Stellos, K, additional, and Stamatelopoulos, K, additional

Published
2022
Full Text
View/download PDF

34. A systematic review and meta-analysis on the effect of selective serotonin reuptake inhibitors on endothelial function

Author

Delialis, D, primary, Mavraganis, G, additional, Dimoula, A, additional, Ajdini, E, additional, Bampatsias, D, additional, Dimopoulou, A M, additional, Sianis, A, additional, Maneta, E, additional, Neofytou, O, additional, Petropoulos, I, additional, Konstantinou, G, additional, Misegiannidis, A, additional, Kokras, N, additional, Stamatelopoulos, K, additional, and Georgiopoulos, G, additional

Published
2022
Full Text
View/download PDF

35. Lp(a) is not associated with arterial stiffness: a Mendelian randomization study

Author

Simistiras, A, primary, Delialis, D, additional, Georgiopoulos, G, additional, Bampatsias, D, additional, Maneta, E, additional, Dimoula, A, additional, Petropoulos, I, additional, Neofytou, O, additional, Oikonomou, E, additional, Kontogiannis, C, additional, Ioannou, S, additional, Miliotou, A, additional, Kanakakis, I, additional, Evangelou, E, additional, and Stamatelopoulos, K, additional

Published
2022
Full Text
View/download PDF

37. The relationship between cardiac injury, inflammation and coagulation in predicting COVID-19 outcome

Author

Mengozzi, A., Georgiopoulos, G., Falcone, M., Tiseo, G., Pugliese, N. R., Dimopoulos, M. A., Ghiadoni, L., Barbieri, G., Forfori, F., Carrozzi, L., Santini, M., Monzani, F., De Marco, S., Menichetti, F., Virdis, A., Masi, S., Sabrina, A. D. I., Martina, B., Matteo, B., Elia, N., Stefano, S., Rachele, A., Valeria, C., Simone, P., Rubia, B., Pietro, B., Giulia, B., Forfori, Francesco, Alessandra, D. R., Fabio, G., Paolo, M., Marco, M., Chiara, P., Alessandro, C., Francesco, C., Naria, P., Luciano, C., Chiara, S., Valentina, G., Uliana, M., Francesca, R., Giovanna, F., and Maria, S.

Subjects
Male, Hemodynamics, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, Prognostic markers, 0302 clinical medicine, Clinical endpoint, Hospital Mortality, Prospective Studies, 030212 general & internal medicine, Prospective cohort study, education.field_of_study, Multidisciplinary, Confounding, Low-Molecular-Weight, Blood Coagulation Disorders, Middle Aged, Prognosis, C-Reactive Protein, Cardiology, Medicine, Female, Risk, medicine.medical_specialty, Heart Diseases, medicine.drug_class, Science, Population, Low molecular weight heparin, Predictive markers, COVID-19, Fibrin Fibrinogen Degradation Products, Heparin, Low-Molecular-Weight, Humans, Inflammation, SARS-CoV-2, Troponin T, Article, 03 medical and health sciences, Internal medicine, medicine, Coagulopathy, education, Heparin, business.industry, medicine.disease, Observational study, business
Abstract

Introduction: High sensitivity troponin T (hsTnT) is a strong predictor of adverse outcome during SARS-CoV-2 infection. However, its determinants remain partially unknown. We aimed to assess the relationship between severity of inflammatory response/coagulation abnormalities and hsTnT in Coronavirus Disease 2019 (COVID-19). We then explored the relevance of these pathways in defining mortality and complications risk and the potential effects of the treatments to attenuate such risk.Methods: In this single-center, prospective, observational study we enrolled 266 consecutive patients hospitalized for SARS-CoV-2 pneumonia. Primary endpoint was in-hospital COVID-19 mortality. Results: hsTnT, even after adjustment for confounders, was associated with mortality. D-dimer and CRP presented stronger associations with hsTnT than PaO2. Changes of hsTnT, D-dimer and CRP were related but only D-dimer was associated with mortality. Moreover, low molecular weight heparin showed attenuation of the mortality in the whole population, particularly in subjects with higher hsTnT.Conclusions: D-dimer possessed a strong relationship with hsTnT and mortality. Anticoagulation treatment showed greater benefits with regard to mortality. These findings suggest a major role of SARS-CoV-2 coagulopathy in hsTnT elevation and its related mortality in COVID-19. A better understanding of the mechanisms related to COVID-19 might pave the way to therapy tailoring in these high-risk individuals.

Published
2021

38. The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk

Author

Pugliese NR, Mengozzi A, Virdis A, Casiglia E, Tikhonoff V, Cicero AFG, Ungar A, Rivasi G, Salvetti M, Barbagallo CM, Bombelli M, Dell'Oro R, Bruno B, Lippa L, D'Elia L, Verdecchia P, Mallamaci F, Cirillo M, Rattazzi M, Cirillo P, Gesualdo L, Mazza A, Giannattasio C, Maloberti A, Volpe M, Tocci G, Georgiopoulos G, Iaccarino G, Nazzaro P, Parati G, Palatini P, Galletti F, Ferri C, Desideri G, Viazzi F, Pontremoli R, Muiesan ML, Grassi G, Masi S, Borghi C, Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension, Pugliese NR, Mengozzi A, Virdis A, Casiglia E, Tikhonoff V, Cicero AFG, Ungar A, Rivasi G, Salvetti M, Barbagallo CM, Bombelli M, Dell'Oro R, Bruno B, Lippa L, D'Elia L, Verdecchia P, Mallamaci F, Cirillo M, Rattazzi M, Cirillo P, Gesualdo L, Mazza A, Giannattasio C, Maloberti A, Volpe M, Tocci G, Georgiopoulos G, Iaccarino G, Nazzaro P, Parati G, Palatini P, Galletti F, Ferri C, Desideri G, Viazzi F, Pontremoli R, Muiesan ML, Grassi G, Masi S, Borghi C, Pugliese, Nicola Riccardo, Mengozzi, Alessandro, Virdis, Agostino, Casiglia, Edoardo, Tikhonoff, Valerie, Cicero, Arrigo F G, Ungar, Andrea, Rivasi, Giulia, Salvetti, Massimo, Barbagallo, Carlo M, Bombelli, Michele, Dell'Oro, Raffaella, Bruno, Berardino, Lippa, Luciano, D'Elia, Lanfranco, Verdecchia, Paolo, Mallamaci, Francesca, Cirillo, Massimo, Rattazzi, Marcello, Cirillo, Pietro, Gesualdo, Loreto, Mazza, Alberto, Giannattasio, Cristina, Maloberti, Alessandro, Volpe, Massimo, Tocci, Giuliano, Georgiopoulos, Georgio, Iaccarino, Guido, Nazzaro, Pietro, Parati, Gianfranco, Palatini, Paolo, Galletti, Ferruccio, Ferri, Claudio, Desideri, Giovambattista, Viazzi, Francesca, Pontremoli, Roberto, Muiesan, Maria Lorenza, Grassi, Guido, Masi, Stefano, Borghi, Claudio, Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension, Cicero AFG, Pugliese, N, Mengozzi, A, Virdis, A, Casiglia, E, Tikhonoff, V, Cicero, A, Ungar, A, Rivasi, G, Salvetti, M, Barbagallo, C, Bombelli, M, Dell'Oro, R, Bruno, B, Lippa, L, D'Elia, L, Verdecchia, P, Mallamaci, F, Cirillo, M, Rattazzi, M, Cirillo, P, Gesualdo, L, Mazza, A, Giannattasio, C, Maloberti, A, Volpe, M, Tocci, G, Georgiopoulos, G, Iaccarino, G, Nazzaro, P, Parati, G, Palatini, P, Galletti, F, Ferri, C, Desideri, G, Viazzi, F, Pontremoli, R, Muiesan, M, Grassi, G, Masi, S, and Borghi, C

Subjects
Male, medicine.medical_specialty, Settore MED/09 - Medicina Interna, Cardiovascular mortality, Prognosi, Sudden cardiac death, chemistry.chemical_compound, Serum uric acid, Risk Factors, Internal medicine, Cause of Death, medicine, Humans, Myocardial infarction, Metabolic syndrome, Prognosis, Stroke, Retrospective Studies, Original Paper, business.industry, Proportional hazards model, Hazard ratio, General Medicine, Middle Aged, medicine.disease, Uric Acid, Survival Rate, chemistry, Italy, Cardiovascular Diseases, Heart failure, Cardiology, Uric acid, Female, Cardiology and Cardiovascular Medicine, business, Biomarkers, Follow-Up Studies
Abstract

Introduction Serum uric acid (SUA) has been depicted as a contributory causal factor in metabolic syndrome (MS), which in turn, portends unfavourable prognosis. Aim We assessed the prognostic role of SUA in patients with and without MS. Methods We used data from the multicentre Uric Acid Right for Heart Health study and considered cardiovascular mortality (CVM) as death due to fatal myocardial infarction, stroke, sudden cardiac death, or heart failure. Results A total of 9589 subjects (median age 58.5 years, 45% males) were included in the analysis, and 5100 (53%) patients had a final diagnosis of MS. After a median follow-up of 142 months, we observed 558 events. Using a previously validated cardiovascular SUA cut-off to predict CVM (> 5.1 mg/dL in women and 5.6 mg/dL in men), elevated SUA levels were significantly associated to a worse outcome in patients with and without MS (all p p = 0.004). Cox regression analyses identified an independent association between SUA and CVM (Hazard Ratio: 1.79 [95% CI, 1.15–2.79]; p p Conclusion Increasing SUA levels are associated with a higher CVM risk irrespective of the presence of MS: a cardiovascular SUA threshold may improve risk stratification. Graphic abstract

Published
2021

41. Glycoprotein acetyls:a novel inflammatory biomarker of early cardiovascular risk in the young

Author

Chiesa, S. T. (Scott T.), Charakida, M. (Marietta), Georgiopoulos, G. (Georgios), Roberts, J. D. (Justin D.), Stafford, S. J. (Simon J.), Park, C. (Chloe), Mykkänen, J. (Juha), Kähönen, M. (Mika), Lehtimäki, T. (Terho), Ala‐Korpela, M. (Mika), Raitakari, O. (Olli), Pietiäinen, M. (Milla), Pussinen, P. (Pirkko), Muthurangu, V. (Vivek), Hughes, A. D. (Alun D.), Sattar, N. (Naveed), Timpson, N. J. (Nicholas J.), Deanfield, J. E. (John E.), Chiesa, S. T. (Scott T.), Charakida, M. (Marietta), Georgiopoulos, G. (Georgios), Roberts, J. D. (Justin D.), Stafford, S. J. (Simon J.), Park, C. (Chloe), Mykkänen, J. (Juha), Kähönen, M. (Mika), Lehtimäki, T. (Terho), Ala‐Korpela, M. (Mika), Raitakari, O. (Olli), Pietiäinen, M. (Milla), Pussinen, P. (Pirkko), Muthurangu, V. (Vivek), Hughes, A. D. (Alun D.), Sattar, N. (Naveed), Timpson, N. J. (Nicholas J.), and Deanfield, J. E. (John E.)

Abstract

Background: Low‐grade inflammation in the young may contribute to the early development of cardiovascular disease. We assessed whether circulating levels of glycoprotein acetyls (GlycA) were better able to predict the development of adverse cardiovascular disease risk profiles compared with the more commonly used biomarker high‐sensitivity CRP (C‐reactive protein). Methods: A total of 3306 adolescents and young adults from the Avon Longitudinal Study of Parents and Children (mean age, 15.4±0.3; n=1750) and Cardiovascular Risk in Young Finns Study (mean age, 32.1±5.0; n=1556) were included. Baseline associations between inflammatory biomarkers, body composition, cardiovascular risk factors, and subclinical measures of vascular dysfunction were assessed cross‐sectionally in both cohorts. Prospective risk of developing hypertension and metabolic syndrome during 9‐to‐10‐year follow‐up were also assessed as surrogate markers for future cardiovascular risk. GlycA showed greater within‐subject correlation over 9‐to‐10‐year follow‐up in both cohorts compared with CRP, particularly in the younger adolescent group (r=0.36 versus 0.07). In multivariable analyses, GlycA was found to associate with multiple lifestyle‐related cardiovascular disease risk factors, cardiometabolic risk factor burden, and vascular dysfunction (eg, mean difference in flow‐mediated dilation=−1.2 [−1.8, −0.7]% per z‐score increase). In contrast, CRP levels appeared predominantly driven by body mass index and showed little relationship to any measured cardiovascular risk factors or phenotypes. In both cohorts, only GlycA predicted future risk of both hypertension (risk ratio [RR], ≈1.1 per z‐score increase for both cohorts) and metabolic syndrome (RR, ≈1.2–1.3 per z‐score increase for both cohorts) in 9‐to‐10‐year follow‐up. Conclusions: Low‐grade inflammation captured by the novel biomarker GlycA is associated with adverse cardiovascular risk profiles from as early as adolescence and predicts f

Published
2022

42. High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid

Author

Palatini, P, Parati, G, Virdis, A, Reboldi, G, Masi, S, Mengozzi, A, Casiglia, E, Tikhonoff, V, Cicero, A, Ungar, A, Rivasi, G, Salvetti, M, Barbagallo, C, Bombelli, M, Dell'Oro, R, Bruno, B, Lippa, L, D'Elia, L, Verdecchia, P, Angeli, F, Mallamaci, F, Cirillo, M, Rattazzi, M, Cirillo, P, Gesualdo, L, Mazza, A, Giannattasio, C, Maloberti, A, Volpe, M, Tocci, G, Georgiopoulos, G, Iaccarino, G, Nazzaro, P, Galletti, F, Ferri, C, Desideri, G, Viazzi, F, Pontremoli, R, Muiesan, M, Grassi, G, Borghi, C, Palatini, Paolo, Parati, Gianfranco, Virdis, Agostino, Reboldi, Gianpaolo, Masi, Stefano, Mengozzi, Alessandro, Casiglia, Edoardo, Tikhonoff, Valerie, Cicero, Arrigo F G, Ungar, Andrea, Rivasi, Giulia, Salvetti, Massimo, Barbagallo, Carlo M, Bombelli, Michele, Dell'Oro, Raffaella, Bruno, Berardino, Lippa, Luciano, D'Elia, Lanfranco, Verdecchia, Paolo, Angeli, Fabio, Mallamaci, Francesca, Cirillo, Massimo, Rattazzi, Marcello, Cirillo, Pietro, Gesualdo, Loreto, Mazza, Alberto, Giannattasio, Cristina, Maloberti, Alessandro, Volpe, Massimo, Tocci, Giuliano, Georgiopoulos, Georgios, Iaccarino, Guido, Nazzaro, Pietro, Galletti, Ferruccio, Ferri, Claudio, Desideri, Giovambattista, Viazzi, Francesca, Pontremoli, Roberto, Muiesan, Maria Lorenza, Grassi, Guido, Borghi, Claudio, Palatini, P, Parati, G, Virdis, A, Reboldi, G, Masi, S, Mengozzi, A, Casiglia, E, Tikhonoff, V, Cicero, A, Ungar, A, Rivasi, G, Salvetti, M, Barbagallo, C, Bombelli, M, Dell'Oro, R, Bruno, B, Lippa, L, D'Elia, L, Verdecchia, P, Angeli, F, Mallamaci, F, Cirillo, M, Rattazzi, M, Cirillo, P, Gesualdo, L, Mazza, A, Giannattasio, C, Maloberti, A, Volpe, M, Tocci, G, Georgiopoulos, G, Iaccarino, G, Nazzaro, P, Galletti, F, Ferri, C, Desideri, G, Viazzi, F, Pontremoli, R, Muiesan, M, Grassi, G, Borghi, C, Palatini, Paolo, Parati, Gianfranco, Virdis, Agostino, Reboldi, Gianpaolo, Masi, Stefano, Mengozzi, Alessandro, Casiglia, Edoardo, Tikhonoff, Valerie, Cicero, Arrigo F G, Ungar, Andrea, Rivasi, Giulia, Salvetti, Massimo, Barbagallo, Carlo M, Bombelli, Michele, Dell'Oro, Raffaella, Bruno, Berardino, Lippa, Luciano, D'Elia, Lanfranco, Verdecchia, Paolo, Angeli, Fabio, Mallamaci, Francesca, Cirillo, Massimo, Rattazzi, Marcello, Cirillo, Pietro, Gesualdo, Loreto, Mazza, Alberto, Giannattasio, Cristina, Maloberti, Alessandro, Volpe, Massimo, Tocci, Giuliano, Georgiopoulos, Georgios, Iaccarino, Guido, Nazzaro, Pietro, Galletti, Ferruccio, Ferri, Claudio, Desideri, Giovambattista, Viazzi, Francesca, Pontremoli, Roberto, Muiesan, Maria Lorenza, Grassi, Guido, and Borghi, Claudio

Abstract

Aims: Whether the association between uric acid (UA) and cardiovascular disease is influenced by some facilitating factors is unclear. The aim of this study was to investigate whether the risk of cardiovascular mortality (CVM) associated with elevated UA was modulated by the level of resting heart rate (HR). Methods and results: Multivariable Cox analyses were made in 19 128 participants from the multicentre Uric acid Right for heArt Health study. During a median follow-up of 11.2 years, there were 1381 cases of CVM. In multivariable Cox models both UA and HR, either considered as continuous or categorical variables were independent predictors of CVM both improving risk discrimination (P ≤ 0.003) and reclassification (P < 0.0001) over a multivariable model. However, the risk of CVM related to high UA (≥5.5 mg/dL, top tertile) was much lower in the subjects with HR

Published
2022

44. CYP1A2 polymorphisms modify the association of habitual coffee consumption with appetite, macronutrient intake, and body mass index: results from an observational cohort and a cross-over randomized study

Author

Gkouskou, K.G. Georgiopoulos, G. Vlastos, I. Lazou, E. Chaniotis, D. Papaioannou, T.G. Mantzoros, C.S. Sanoudou, D. Eliopoulos, A.G.

Abstract

Background/Objectives: Evidence regarding the influence of coffee on appetite and weight control is equivocal and the influence of covariates, such as genetic variation in caffeine metabolism, remains unknown. Herein, we addressed the novel hypothesis that genetic variation in CYP1A2, a gene responsible for more than 95% of caffeine metabolism, differentially impacts the association of coffee consumption with appetite and BMI among individuals with different genetic predispositions to obesity. Subjects/Methods: A cross-over randomized intervention study involving 18 volunteers assessed the effects of coffee consumption on dietary intake, appetite, and levels of the appetite-controlling hormones asprosin and leptin. Data on habitual coffee intake, BMI, and perceived appetite were obtained from an observational cohort of 284 volunteers using validated questionnaires. Participants were stratified according to a validated genetic risk score (GRS) for obesity and to the −163C > A (rs762551) polymorphism of CYP1A2 as rapid (AA), intermediate (AC), or slow (CC) caffeine metabolizers. Results: Coffee consumption led to lower energy and dietary fat intake and circulating asprosin levels (P for interaction of rs762551 genotype*coffee consumption=0.056, 0.039, and 0.043, respectively) as compared to slow/intermediate metabolizers. High coffee consumption was more prevalent in rapid compared to slow metabolizers (P = 0.008 after adjustment for age, sex, and BMI) and was associated with lower appetite perception and lower BMI only in rapid metabolizers (P for interaction of rs762551 genotype*coffee consumption = 0.002 and 0.048, respectively). This differential association of rs762551 genotype and coffee consumption with BMI was more evident in individuals at higher genetic risk of obesity (mean adjusted difference in BMI = −5.82 kg/m2 for rapid versus slow/intermediate metabolizers who consumed more than 14 cups of coffee per week). Conclusions: CYP1A2 rs762551 polymorphism modifies the association of habitual coffee consumption with BMI, in part by influencing appetite, energy intake and circulating levels of the orexigenic hormone asprosin. This association is more evident in subjects with high genetic predisposition to obesity. ClinicalTrials.gov: registered Clinical Trial NCT04514588. © 2021, The Author(s), under exclusive licence to Springer Nature Limited.

Published
2022

45. Clinical frailty, and not features of acute infection, is associated with late mortality in COVID-19: a retrospective cohort study

Author

Vlachogiannis, N.I. Baker, K.F. Georgiopoulos, G. Lazaridis, C. van der Loeff, I.S. Hanrath, A.T. Sopova, K. Tual-Chalot, S. Gatsiou, A. Spyridopoulos, I. Stamatelopoulos, K. Duncan, C.J.A. Stellos, K.

Abstract

Background: Coronavirus disease 2019 (COVID-19) is associated with excess mortality after hospital discharge. Identification of patients at increased risk of death following hospital discharge is needed to guide clinical monitoring and early intervention. Herein, we aimed to identify predictors of early vs. late mortality in COVID-19 patients. Methods: A total of 471 patients with polymerase chain reaction-confirmed COVID-19 were followed up for 9 months [median (inter-quartile range) of follow-up time: 271 (14) days] after hospital admission. COVID-19-related signs and symptoms, laboratory features, co-morbidities, Coronavirus Clinical Characterisation Consortium (4C) mortality and Clinical Frailty Scale (CFS) scores were analysed by logistic regression for association with early (28 day) vs. late mortality. Receiver operating characteristic (ROC) analysis was used to determine the discriminative value of 4C and CFS scores for early vs. late mortality. Results: A total of 120 patients died within 28 days from hospital admission. Of the remaining 351 patients, 41 died within the next 8 months. Respiratory failure, systemic inflammation, and renal impairment were associated with early mortality, while active cancer and dementia were associated with late mortality, after adjustment for age and sex. 4C mortality score and CFS were associated with both early [odds ratio (OR) (95% confidence interval—CI): 4C: 1.34 (1.25–1.45); CFS: 1.49 (1.33–1.66)] and late [OR (95% CI): 4C: 1.23 (1.12–1.36); CFS: 2.04 (1.62–2.56)] mortality. After adjustment for CFS, the association between 4C and late mortality was lost. By ROC analysis, 4C mortality score was superior to CFS for 28 day mortality [area under the curve (AUC) (95% CI): 0.779 (0.732–0.825) vs. 0.723 (0.673–0.773), respectively; P = 0.039]. In contrast, CFS had higher predictive value for late mortality compared with 4C mortality score [AUC (95% CI): 0.830 (0.776–0.883) vs. 0.724 (0.650–0.798), respectively; P = 0.007]. Conclusions: In our cohort, late mortality in COVID-19 patients is more strongly associated with premorbid clinical frailty than with severity of the acute infection phase. © 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.

Published
2022

46. Temporal trends in stroke incidence and case-fatality rates in Arcadia, Greece: A sequential, prospective, population-based study

Author

Karantali, E. Vemmos, K. Tsampalas, E. Xynos, K. Karachalia, P. Lambrou, D. Angeloglou, S. Kazakou, M. Karagianni, A. Aravantinou-Fatorou, K. Karakatsani, E. Bots, M.L. Karamatzianni, G. Bellos, S. Ntiloudis, R. Lypiridou, M. Gamvoula, A. Georgiopoulos, G. Ajdini, E. Gatselis, N. Makaritsis, K. Korompoki, E. Ntaios, G.

Abstract

Background: Stroke incidence and case-fatality are reported to decline in high-income countries during the last decades. Epidemiological studies are important for health services to organize prevention and treatment strategies. Aims: The aim of this population-based study was to determine temporal trends of stroke incidence and case-fatality rates of first-ever stroke in Arcadia, a prefecture in southern Greece. Methods: All first-ever stroke cases in the Arcadia prefecture were ascertained using the same standard criteria and multiple overlapping sources in three study periods: from November 1993 to October 1995; 2004; and 2015–2016. Crude and age-adjusted to European population incidence rates were compared using Poisson regression. Twenty-eight days case fatality rates were estimated and compared using the same method. Results: In total, 1315 patients with first-ever stroke were identified. The age-standardized incidence to the European population was 252 per 100,000 person-years (95% CI 231–239) in 1993/1995, 252 (95% CI 223–286) in 2004, and 211 (192–232) in 2015/2016. The overall age- and sex-adjusted incidence rates fell by 16% (incidence rates ratio 0.84, 95% CI: 0.72–0.97). Similarly, 28-day case-fatality rate decreased by 28% (case fatality rate ratio = 0.72, 95% CI: 0.58–0.90). Conclusions: This population-based study reports a significant decline in stroke incidence and mortality rates in southern Greece between 1993 and 2016. © 2021 World Stroke Organization.

Published
2022

47. High-sensitivity troponins for outcome prediction in the general population: a systematic review and meta-analysis

Author

Aimo, A. Georgiopoulos, G. Panichella, G. Vergaro, G. Passino, C. Emdin, M. Clerico, A.

Abstract

Background: High-sensitivity (hs) assays allow to measure cardiac troponin T and I (cTnT/I) even in healthy individuals. The higher hs-cTn values, the higher the ongoing cardiomyocyte damage, and then reasonably the risk of developing symptomatic cardiac disease. Methods: We retrieved all studies evaluating the prognostic value of hs-cTnT or I in the general population. We calculated pooled hazard ratio (HR) values for all-cause and cardiovascular death, cardiovascular events and heart failure (HF) hospitalization. Results: We included 24 studies for a total of 203,202 subjects; 11 studies assessed hs-cTnT and 14 hs-cTnI. One standard deviation (SD) increase in baseline hs-cTn was associated with a 23% higher risk of all-cause death (HR 1.226, 95% CI 1.083-1.388, p

Published
2022

48. COVID-19 and myocarditis: a systematic review and overview of current challenges

Author

Castiello, T. Georgiopoulos, G. Finocchiaro, G. Claudia, M. Gianatti, A. Delialis, D. Aimo, A. Prasad, S.

Abstract

Myocardial inflammation in COVID-19 has been documented. Its pathogenesis is not fully elucidated, but the two main theories foresee a direct role of ACE2 receptor and a hyperimmune response, which may also lead to isolated presentation of COVID-19-mediated myocarditis. The frequency and prognostic impact of COVID-19-mediated myocarditis is unknown. This review aims to summarise current evidence on this topic. We performed a systematic review of MEDLINE and Cochrane Library (1/12/19–30/09/20). We also searched clinicaltrials.gov for unpublished studies testing therapies with potential implication for COVID-19-mediated cardiovascular complication. Eligible studies had laboratory confirmed COVID-19 and a clinical and/or histological diagnosis of myocarditis by ESC or WHO/ISFC criteria. Reports of 38 cases were included (26 male patients, 24 aged < 50 years). The first histologically proven case was a virus-negative lymphocytic myocarditis; however, biopsy evidence of myocarditis secondary to SARS-CoV-2 cardiotropism has been recently demonstrated. Histological data was found in 12 cases (8 EMB and 4 autopsies) and CMR was the main imaging modality to confirm a diagnosis of myocarditis (25 patients). There was a substantial variability in biventricular systolic function during the acute episode and in therapeutic regimen used. Five patients died in hospital. Cause-effect relationship between SARS-CoV-2 infection and myocarditis is difficult to demonstrate. However, current evidence demonstrates myocardial inflammation with or without direct cardiomyocyte damage, suggesting different pathophysiology mechanisms responsible of COVID-mediated myocarditis. Established clinical approaches should be pursued until future evidence support different actions. Large multicentre registries are advisable to elucidate further. © 2021, The Author(s).

Published
2022

49. Echocardiographic and Cardiac Magnetic Resonance Imaging-Derived Strains in Relation to Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy

Author

Klettas, D. Georgiopoulos, G. Rizvi, Q. Oikonomou, D. Magkas, N. Bhuva, A.N. Manisty, C. Captur, G. Aimo, A. Nihoyannopoulos, P.

Abstract

We compared speckle tracking echocardiography (STE) and feature tracking cardiovascular magnetic resonance (FT-CMR) in patients with hypertrophic cardiomyopathy (HC) with a varying extent of fibrosis as defined by late gadolinium enhancement to look at the level of agreement between methods and their ability to relate those to myocardial fibrosis. At 2 reference centers, 79 patients with HC and 16 volunteers (the control group) underwent STE and CMR with late gadolinium enhancement and FT-CMR. Patients were classified into 3 categories: no detectable, limited, and extensive fibrosis. Global longitudinal strain (GLS) and global radial strain (GRS) were derived using FT-CMR and STE. STE-derived GRS was decreased in all HC categories compared with the control group (p

Published
2022

50. Assessment of frailty and related outcomes in older patients with heart failure: A cohort study

Author

Tournas, G. Kourek, C. Mantzaraki, V. Georgiopoulos, G. Pantos, C. Toumanidis, S. Briasoulis, A. Paraskevaidis, I.

Abstract

Objective: Heart failure (HF) is a common cause of morbidity and mortality in older patients. Frailty is prevalent and complicates the course of HF. We sought to investigate the impact of frailty on HF outcomes. Methods: Patients over 65 years old hospitalized with acute decompensated HF and mildly reduced or preserved EF, between September 2017 and September 2019 were enrolled in the study. Before hospital discharge at euvolemic state, patients underwent six-minute walk test (6MWT) and frailty assessment using FRIED and modified SOF scores. Predictors of death, readmissions, and increase in diuretic dose were analyzed by multivariable logistic regression models. Results: We enrolled 193 consecutive patients (mean age 78.6 ± 8.4 years, 29.5% males, 59.6% with HF and preserved EF). All patients had at least one comorbidity (40.9% coronary artery disease, 71% diabetes, and 86% hypertension). The mean 6MWT distance was 316.2 meters. According to FRIED score, 4.7% were normal and 17.6% were categorized as pre-frail and 77.7% as frail, while according to SOF index 9.8% were normal, 15% were categorized as pre-frail and 75.1% as frail. Frail patients according to both indices had a higher risk of 90-day readmissions, uptitration of diuretics within 90 days (p < 0.001 for both) and numerically but not significantly higher risk of death. Frailty status was independently associated with higher risk of 90-day readmissions, uptitration of diuretics, and higher BNP at 90 days. Conclusions: Frailty in older patients with HF is common and associated with worse prognosis. Pre-discharge frailty assessment may aid in identification of patients at high-risk for short-term complications. © 2022 Hellenic Society of Cardiology

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results